Serum tumor markers in breast cancer: Are they of clinical value?

Clinical Chemistry

Volumn 52, Issue 3, 2006, Pages 345-351

  Duffy, Michael J ^a,b,c  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c Dublin Molecular Medicine Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADVANCED CANCER; BREAST CANCER; CLINICAL ASSESSMENT; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY CANCER; HUMAN; PREOPERATIVE EVALUATION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; FEMALE; HUMANS; PRACTICE GUIDELINES; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SERUM;

EID: 33644544070     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.059832     Document Type: Short Survey

References (67)

1. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1977;337:242-51.
2. Fisher PM, Hancock BW. Gestational trophoblastic disease and their treatment. Cancer Treat Rev 1997;23:1-16.
3. Rustin GJS. Use of CA 125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003;21(10 Suppl):187s-93s.
4. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? [Review]. Clin Chem 2001;47:624-30.
5. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004;5:101-6.
6. Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 1999;36:579-86.
7. Cheung K, Graves CRL, Robertson JFR. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000;26:91-102.
8. Nicolini A, Carpi A. Postoperative follow-up of breast cancer patients: overview of progress in the use of tumor markers. Tumor Biol 2000;21:235-48.
9. Anonymous. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-77.
10. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. Crit Rev Oncol Haematol 1999;31:209-23.
11. Isaacs C, Stearns V, Hayes DF. New prognostic factors for breast cancer. Semin Oncol 2001;28:53-67.
12. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002;48:1194-7.
13. Horobin JM, Browning MCK, McFarlane NP, Smith G, Preece PE, Wood RA, et al. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer. J R Coll Surg Edinb 1991;36:219-21.
14. Iaffaioli RV, Caponigro F, Esposito G, Pagharulo C, Deplacido S, Ungaro B, et al. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Int J Biol Markers 1991;6:21-4.
15. Shering S, Sherry F, McDermott E, O'Higgins N, Duffy MJ. Preoperative CA 15-3 concentrations predict outcome in breast cancer. Cancer 1998;83:2521-7.
16. Molina R, Jo J, Filella X, Zamon G, Palisa J, Munoz M, et al. c-erbB-2 oncoprotein, CEA and CA 15-3 in patients with breast cancer. Breast Cancer Res Treat 1998;51:109-19.
17. Vialard F, Basuyau JP, Gligorov J, Bocara C, Graic Y, Veyret C, et al. CA 15-3: prognostic factor in breast cancer [Abstract]. Eur J Cancer 1998;34(Suppl 5):S100.
18. McLaughlin R, McGrath J, Grimes H, Given HF. The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 2000;15:340-2.
19. Canizares F, Sola J, Perez M, Tovar I, De Las Heras M, Salinas J, et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol 2002;22:273-81.
20. Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, et al. Prognostic role of serum CA 15.3 in 362 node-negative breast cancer. An old player for a new game. Eur J Cancer 2002;38:1181-8.
21. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002;22:1217-22.
22. Kumpulainen EJ, Keskikuru R, Johansson RT. Serum tumor marker CA 15.3 and stage are the two most important predictors of survival in primary breast cancer. Breast Cancer Res Treat 2002;76:95-102.
23. Duffy MJ, Duggan C, Keane R, Hill ADK, McDermorr E, Crown J, et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004;50:559-63.
24. Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, et al. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res 2003;23:1035-42.
25. Tampellini M, Berutti A, Gerbino A, Buniva T, Torta M, Gorzegno G, et al. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 1997;75:698-702.
26. De La Lande B, Hacene K, Floiras J-L, Alatrakchi N, Pichon M-F. Prognostic value of CA 15-3 kinetics for metastatic breast cancer. Int J Biol Markers 2002;17:231-8.
27. Carney WP, Neuman R, Lipton A, Price C. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003;49:1579-98.
28. Duffy MJ. Predictive markers in breast and other cancers. Clin Chem 2005;51:494-503.
29. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004;5:163-75.
30. The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 1994;271:1587-92.
31. Rosselli del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994;271:1593-7.
32. Rojas MP, Telaro E, Russo A, Fossati R, Palli D, Rosselli del Turco M, et al. Follow-up strategies for women treated for early brefest cancer. Cochrane Database Syst Rev 2004;1:CD001768.
33. Collins RF, Bekker HL, Dodwell DJ. Follow-up care of patients treated for breast cancer: a structured review. Cancer Treat Rev 2004;30:19-35.
34. Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol 2003;30:338-48.
35. Crivelari D, Price KN, Hagen M, Goldhirch A, Gelber RD, Castiglione M, et al. Routine tests during follow-up of patients after primary treatment for operable breast cancer. Ann Oncol 1995;6:769-76.
36. Mariani G. New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. Ann Oncol 2005;16(Suppl ii):91-4.
37. Jager W. Disseminated breast cancer: does early treatment prolong survival without symptoms? [Abstract]. Breast 1995:4 65.
38. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 1997;76:1106-11.
39. Nicolini A, Carpi A, Michelassi C, Spinelli C, Conte M, Miccoli P, et al. "Tumor marker guided" salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed Pharmacother 2003;57:452-9.
40. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S. Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol 1994;35:80-3.
41. Bast RC, Ravdin P, Hayes DF, Bates S, Pritsche H, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
42. Blamey RW. Guidelines on endocrine therapy of breast cancer, EUSOMA. Eur J Cancer 2002;38:615-34.
43. European Society of Medical Oncology. ESMO minimal clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol 2005;16(Suppl 1):17-9.
44. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer: European Group of Tumor Markers (EGTM) recommendations. Tumor Biol 2005;26:281-93.
45. Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Wittliff J. Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamindis EP, Fritsche H, Scharwtz MK, Chan DW, eds. Tumor markers, physiology, pathobiology, technology and clinical applications. Chicago: AACC Press, 2002:33-63.
46. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977;13:89-94.
47. Williams MR, Turkes A, Pearson D, Griffiths K, Blamey RW. An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. Br J Cancer 1990;61:126-32.
48. Robertson JFR, Pearson D, Price MR, Selby C, Blamey RW, Howell A. Objective measurement of therapeutic response in breast cancer using tumor markers. Br J Cancer 1991;64:757-63.
49. Dixon AR, Jackson L, Chan SY, Badley RA, Blamey RW. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? Br J Cancer 1993;68:181-5.
50. Robertson JFR, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumor markers. Eur J Cancer 1999;35:47-53.
51. Van Dalen A, Heering KJ, Barak V, Peretz T, Cremaschi A, Geroni P, et al. Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumor marker changes. Breast 1996;5:82-8.
52. Kurebayashi J, Nishimura R, Tanaka K, Kohno N, Kurosumi M, Moriya T, et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer 2004;11:389-95.
53. Vogel CL, Tan-Chiu E. Trastuzumab plus chemotherapy: convincing survival or not? J Clin Oncol 2005;19:1-4.
54. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, et al. Clinical utility of serum HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005;7:R436-43.
55. Kostler WJ, Schwab B, Singer CF, Neuman R, Rucklinger E, Brodowicz T, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004;10:1618-24.
56. Colomber R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast cancer correlate with extent of metastatic disease. Cancer 1989;64:1674-81.
57. Geraghty JG, Coveney EC, Sherry F, O'Higgins NJ, Duffy MJ. CA 15-3 in patients with locoregional and metastatic breast cancer. Cancer 1992;70:2831-4.
58. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA 15-3 assays in detecting relapse in patients with breast cancer. Breast Cancer Res Treat 1995;36:41-8.
59. Kokko R, Holli K, Hakama M. CA 15-3 in the follow-up of localised breast cancer. Eur J Cancer 2002;38:1189-93.
60. Soletormos G, Schioler V, Nielsen D, Skovsgaard T, Dombernowsky P. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem 1993;39:2077-83.
61. Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990;65:193-9.
62. Hayes DF, Kiang DT, Korzun AH, Tondini C, Wood WC, Kufe DW. CA15-3 and CEA spikes during chemotherapy for metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 1988;7:38.
63. Yasasever V, Dincer M, Camlica H, Karalogiu D, Dalay N. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastasis: special emphasis on "spiking" phenomena. Clin Biochem 1997;30:53-6.
64. Pentheroudakis G, Malamou-Mitsi V, Briasoulis E, Damala K, Vassou A, Vartholomatos G, et al. The neutrophil, not the tumor, serum CA 15-3 elevation as a result of granulocyte-colony-stimulating factor-induced neutrophil MUC1 overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy. Cancer 2004;101:1767-75.
65. Colomer CR, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R, et al. Circulating CA 15-3 levels in the postsurgical follow-up breast cancer patients and in non-malignant disease. Breast Cancer Res Treat 1989;13:123-33.
66. Hashimoto T, Matsubara F. Changes in the tumor marker concentration in female patients with hyper-, eu-, and hyperthyroidism. Endocrinol Jpn 1989;36:873-9.
67. 12 deficiency. Oncology 2004;67:359-67.